SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China

NEXT STORY
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
PREV STORY
New Study Demonstrates Clinical Utility of PrismRA® Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GBS Inc. Announces its Pre-Submission package is with the FDA

author_avatar
NASDAQ Market News

Cell Design Labs Announces Peer-Reviewed Publication Validating Ability to Program Immune Cells to Treat Cancer and Autoimmune Disease

-- Researchers Show Combining Universal Cell Sensor with T Cells Creates Cellular “Robots” that ...

author_avatar
NASDAQ Market News

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

author_avatar
NASDAQ Market News